查詢結果分析
相關文獻
- 第一個針對BRCA突變卵巢癌的標靶治療:Olaparib
- Obturator Mononeuropathy: A Rare Clinical Presentation of Ovarian Cancer
- 雙側卵巢Krukenberg腫瘤之皮膚轉移
- 靈芝水溶液對婦癌細胞生長之抑制效果
- 三株卵巢癌細胞株變異生長因子之表現
- 卵巢癌的治療 (日本人的經驗談)
- 突兀凶狠的卵巢癌
- Primary Retroperitoneal Liposarcoma Mimicking Ovarian Cancer: A Case Report
- Ovarian Cancer after Hysterectomy: A Case Report
- 白血球生成素(Granulocyte Clony Stimulating Factor, G-CSF)及維生素A酸(Retinoic Acid, R.A.)對卵巢癌細胞株OC-117-VGH細胞BRCA1 and BRCA2的影響
頁籤選單縮合
題名 | 第一個針對BRCA突變卵巢癌的標靶治療:Olaparib=The First Targeted Therapy toward BRCA-mutated Ovarian Cancer: Olaparib |
---|---|
作者姓名(中文) | 姜紹青; | 書刊名 | 腫瘤護理雜誌 |
卷期 | 18:2 2018.12[民107.12] |
頁次 | 頁13-20 |
分類號 | 418.31 |
關鍵詞 | 乳癌易感基因; 卵巢癌; DNA受損反應路徑; BRCA; Breast cancer susceptibility gene; Ovarian cancer; DNA damage response pathway; DDR; Olaparib; |
語文 | 中文(Chinese) |
中文摘要 | 表皮卵巢癌是全世界女性第七名高的發生率。台灣女性癌症中的第九高。在2006至2013年間,雖然全球的重大研究中,沒有任何一個新藥在治療卵巢癌領域被核准。Olaparib在2014首度在美國食物藥品管理署被核准單一治療用於具有傷害性或懷疑的BRCA突變晚期且已經三或更多的化學治療;2017年再加上具有乳癌易感基因(breast cancer susceptibility gene,BRCA)突變的卵巢癌,對鉑類化療已經完全或部分反應後之維持療法。2018年6月5日olaparib在臺灣取得許可證。Olaparib是PARP酵素抑制劑的第一個上市藥品。PARP酵素在DNA受損反應路徑(DDR)特別是鹼基排除修護(BER)或單股斷片修護(SSBR)負責DNA受損修護的工作。臨床試驗(SOLO-2)中,證實在具有生殖細胞BRCA突變的卵巢癌、輸卵管癌、原發腹膜癌的病人,先前都接受過鉑化學治療,且最近一次對於鉑化學治療有萬全或部分反應者,Olaparib被證實可以延長無惡化存活期。主要副作用為血液學副作用,極少數(<1%)病人在試驗中發生骨髓增生不良症候群與急性骨髓性白血病,所以接受本藥的病人,需要有全血球計數的基線值與定期檢測。 |
英文摘要 | Epithelial ovarian cancer ranks top seven in female cancer incidence worldwide and top nine in Taiwan. From 2006 to 2013, there was not any antineoplastic agent approved for this disease. In 2014, US FDA approved the first targeted agent, Olaparib, for BRCA-mutated ovarian cancer after 3 or more prior chemotherapy. Then in 2017, Olaparib was approved for BRCA mutation maintenance after complete/partial response to platinum chemotherapy. Taiwan also gave her FDA approval to Olaparib in June, 2018. The mechanism of Olaparib is to inhibit poly(ADP-ribose) polymerase, which plays a vital role in the DNA damage repair. In the SOLO 2 trial, a phase III trial for ovarian, fallopian, and primary peritoneal cancer, patients with BRCA mutation maintenance therapy after complete/partial response to platinum chemotherapy responded to Olaparib with prolonged progression-free survival. The major adverse effects of Olaparib are mainly hematological. Very few (<1%) patients in the clinical trial showed myelodysplastic syndrome or acute mylogenous leukemia after the start of therapy. Baseline and periodical complete blood counts need to be monitored. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。